4//SEC Filing
Luu Brendan 4
Accession 0001062993-22-004522
CIK 0001177648other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 9:54 PM ET
Size
8.5 KB
Accession
0001062993-22-004522
Insider Transaction Report
Form 4
Luu Brendan
Chief Business Officer
Transactions
- Award
Common Stock
2022-02-14+286→ 7,086 total - Tax Payment
Common Stock
2022-02-14$62.49/sh−489$30,558→ 7,723 total - Award
Common Stock
2022-02-14+1,126→ 8,212 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeother
Related Parties
1- filerCIK 0001842369
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 9:54 PM ET
- Size
- 8.5 KB